Cellebrite DI Ltd.
CLBT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5 | $2 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 23.4% | 20.1% | 9.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 84.4% | 83.6% | 81.3% | 82.7% |
| EBITDA | $0 | -$0 | $0 | $0 |
| % Margin | 16.8% | -19.9% | 48.1% | 36.3% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -70.5% | -24.9% | 44.6% | 29% |
| EPS Diluted | -1.35 | -0.43 | 0.59 | 0.44 |
| % Growth | -214% | -172.9% | 34.1% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |